cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma

Cancer Chemother Pharmacol. 1983;11(1):35-7. doi: 10.1007/BF00257414.

Abstract

From December 1981 to November 1982, a consecutive series of 37 patients with advanced non-oat cell bronchogenic carcinoma were treated with cis-platinum and etoposide in doses of 20 mg/m2 and 75 mg/m2, respectively, for 5 consecutive days every 3 weeks. Among the 33 evaluable patients, one complete response, 11 partial responses, five minor responses, seven unchanged states, and nine cases of progression were noted. Median duration of response was 30+ weeks. Toxicity was significant, but no treatment-related deaths were encountered. Combined cis-platinum and etoposide can provide significant palliation in approximately one-third of patients with the doses and schedule used.

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Bronchogenic / drug therapy*
  • Carcinoma, Bronchogenic / radiotherapy
  • Cisplatin / therapeutic use*
  • Drug Therapy, Combination
  • Etoposide / therapeutic use*
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / radiotherapy
  • Male
  • Middle Aged
  • Podophyllotoxin / analogs & derivatives*

Substances

  • Etoposide
  • Podophyllotoxin
  • Cisplatin